pilot study of systemic combination therapy with TS-1 and IFN for hepatocellular carcinoma patients with extrahepatic metastases who do not response to systemic combination therapy with TS-1 and cisplatin.
Not Applicable
- Conditions
- hepatocellular carcinoma with extrahepatic metastases
- Registration Number
- JPRN-UMIN000002929
- Lead Sponsor
- Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical, Hiroshima University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1) With other malignant disease. 2) A pregnant woman, or a woman suspected of pregnancy. 3) With severe infectious disease. 4) With history of severe allergy. 5) With severe renal function disease. 6) With severe allergy for 5FU, TS-1 or IFN. 7) With severe bone marrow supression. 8) With pulmonary fibrosis. 9) With another fluoropyrimidine 10)With flucytosine 9) with shosaikoto 10) with autoimmune hepatitis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method 1) overall survival 2) time to progression 3) safety